ArticleBreast cancer (Tokyo, Japan)2026
A phase II study combining radiotherapy and atezolizumab/nab-paclitaxel for inoperable or recurrent programmed death-ligand 1-positive triple-negative breast cancer: IMRad-Br study protocol and safety run-in.
Hiroshi Ishiguro et al.PubMed ↗Publisher ↗
No numbers read from the abstract.